Nine major European drugmakers warn the region risks losing pharma investment, Novartis licenses a preclinical radioligand ...

The best CI partner isn't the one with the most data — it's the one willing to tell you your assumptions are wrong. Pharma ...

Chief executives from nine of Europe's largest drugmakers are calling on the European Union (EU) and its member states to ...

The FDA's movement to encourage real-world data use through downstream acceptance is, in effect, a call to action for ...

BoomRay Pharmaceuticals entered into an exclusive global license agreement with Novartis for an undisclosed preclinical ...

Welcome to Pharmaceutical Executive Daily, your quick briefing on the top news shaping the pharmaceutical and life sciences ...

Elaine Ferguson, global president at Inizio Medical, spoke with Pharmaceutical Executive about the importance of both managing and growing talent. In today’s world, this requires people already in ...

Novo Nordisk reports that CagriSema delivered 12.4% average weight loss in a late-stage diabetes trial, outperforming tirzepatide's 9.1% at comparable doses.

As GLP-1 competition shifts from molecules to prescriptions, manufacturers, pharmacies, providers, and payers are racing to ...

FDA approves Kerendia as the first new treatment for kidney disease in type 1 diabetes in decades, Novo, Roche, and Aethlon ...

AbbVie partners with Iambic to deploy its AI molecular superintelligence platform, while Telix Pharmaceuticals agrees to acquire radioisotope leader ITM.

GSK is acquiring a trispecific T-cell engager from Chimagen Biosciences and Sanofi expanding its manufacturing partnership ...